中国东北地区原发性胆汁性胆管炎患者抗 gp210 抗体的预后价值。

The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China.

机构信息

Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin, China.

Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin, China.

出版信息

Dig Liver Dis. 2022 Aug;54(8):1094-1100. doi: 10.1016/j.dld.2021.10.011. Epub 2021 Nov 15.

DOI:10.1016/j.dld.2021.10.011

PMID:34789400

Abstract

BACKGROUND

Whether the anti-gp210 antibody can be used as a biomarker in patients with primary biliary cholangitis (PBC) remains controversial.

AIMS

We aimed to investigate the association between anti-gp210 antibodies and prognosis in ursodeoxycholic acid (UDCA)-treated PBC patients.

METHODS

We conducted a retrospective cohort study of 180 UDCA-treated PBC patients to assess the prognostic value of anti-gp210 antibodies using the Kaplan-Meier method and Cox proportional hazard regression analysis.

RESULTS

Of the patients included in our analysis, 50 (27.8%) were anti-gp210 positive, and 130 (72.2%) were anti-gp210 negative. The incidence of liver-related death or transplantation was more common in the anti-gp210 + group (22.0 vs. 9.2%, P=0.022). The five-year transplant-free survival rates of anti-gp210-positive patients vs. anti-gp210-negative patients were 77.0% and 90.3%, respectively. We found that the probability of transplant-free survival was significantly lower in the anti-gp210-positive patients than in the anti-gp210-negative patients (log-rank P=0.004). After adjusting for potential confounders using multivariable Cox regression model, positivity for anti-gp210 antibody (hazard ratio: 4.619, 95% confidence interval: 1.895-11.261, P=0.001) was found to be independently associated with an increase in liver-related mortality or transplantation.

CONCLUSION

In this cohort of UDCA-treated PBC patients, positivity for anti-gp210 antibody was independently associated with a higher risk of liver-related death or transplantation.

摘要

背景

抗 gp210 抗体能否作为原发性胆汁性胆管炎（PBC）患者的生物标志物仍存在争议。

目的

我们旨在研究熊去氧胆酸（UDCA）治疗的 PBC 患者中抗 gp210 抗体与预后的关系。

方法

我们进行了一项回顾性队列研究，纳入了 180 例接受 UDCA 治疗的 PBC 患者，采用 Kaplan-Meier 方法和 Cox 比例风险回归分析评估抗 gp210 抗体的预后价值。

结果

在我们的分析中，50 例（27.8%）患者抗 gp210 阳性，130 例（72.2%）患者抗 gp210 阴性。抗 gp210 + 组的肝相关死亡或移植发生率更高（22.0%比 9.2%，P=0.022）。抗 gp210 阳性患者与抗 gp210 阴性患者的五年无移植生存率分别为 77.0%和 90.3%。我们发现，抗 gp210 阳性患者的无移植生存率明显低于抗 gp210 阴性患者（对数秩检验 P=0.004）。使用多变量 Cox 回归模型调整潜在混杂因素后，抗 gp210 抗体阳性（风险比：4.619，95%置信区间：1.895-11.261，P=0.001）与肝相关死亡率或移植的增加独立相关。